|
|
Volumn 14, Issue 1, 2003, Pages 55-59
|
|
Mortality of cystic fibrosis patients treated with tobramycin solution for inhalation
a
|
|
Author keywords
Cohort study; Confounding; Confounding by indication; Cystic fibrosis; Mortality; Selection bias
|
|
Indexed keywords
PLACEBO;
TOBRAMYCIN;
ANTIINFECTIVE AGENT;
ADULT;
ARTICLE;
BACTERIAL INFECTION;
COHORT ANALYSIS;
CYSTIC FIBROSIS;
DRUG EFFECT;
FEMALE;
HIGH RISK PATIENT;
HUMAN;
LUNG FUNCTION;
MAJOR CLINICAL STUDY;
MALE;
MORTALITY;
PRIORITY JOURNAL;
PSEUDOMONAS AERUGINOSA;
RETROSPECTIVE STUDY;
RISK BENEFIT ANALYSIS;
TREATMENT INDICATION;
ADOLESCENT;
CHILD;
EPIDEMIOLOGY;
GRAM NEGATIVE INFECTION;
INFANT;
INHALATIONAL DRUG ADMINISTRATION;
MICROBIOLOGY;
MIDDLE AGED;
NEWBORN;
PRESCHOOL CHILD;
REGISTER;
RISK FACTOR;
UNITED STATES;
ADMINISTRATION, INHALATION;
ADOLESCENT;
ADULT;
ANTI-BACTERIAL AGENTS;
CHILD;
CHILD, PRESCHOOL;
CONFOUNDING FACTORS (EPIDEMIOLOGY);
CYSTIC FIBROSIS;
HUMANS;
INFANT;
INFANT, NEWBORN;
MIDDLE AGED;
PSEUDOMONAS AERUGINOSA;
PSEUDOMONAS INFECTIONS;
REGISTRIES;
RISK FACTORS;
SELECTION BIAS;
TOBRAMYCIN;
UNITED STATES;
|
|
EID: 0037209069
PISSN: 10443983
EISSN: None
Source Type: Journal
DOI: 10.1097/00001648-200301000-00014 Document Type: Article |
|
Times cited : (33)
|
|
References (4)
|
